Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
Status: | Recruiting |
---|---|
Conditions: | Colorectal Cancer, Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 3/31/2019 |
Start Date: | February 2, 2017 |
End Date: | November 30, 2023 |
A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
This randomized phase III trial compares nephrectomy (surgery to remove a kidney or part of a
kidney) with or without nivolumab in treating patients with kidney cancer that is limited to
a certain part of the body (localized). Immunotherapy with monoclonal antibodies, such as
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Giving nivolumab before nephrectomy may make the
tumor smaller and reduce the amount of normal tissue that needs to be removed, and after
nephrectomy to increase survival. It is not yet known whether nivolumab and nephrectomy is
more effective than nephrectomy alone in treating patients with kidney cancer.
kidney) with or without nivolumab in treating patients with kidney cancer that is limited to
a certain part of the body (localized). Immunotherapy with monoclonal antibodies, such as
nivolumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread. Giving nivolumab before nephrectomy may make the
tumor smaller and reduce the amount of normal tissue that needs to be removed, and after
nephrectomy to increase survival. It is not yet known whether nivolumab and nephrectomy is
more effective than nephrectomy alone in treating patients with kidney cancer.
PRIMARY OBJECTIVES:
I. To compare recurrence-free survival (RFS) between patients with locally advanced renal
cell carcinoma randomly assigned to perioperative nivolumab in conjunction with radical or
partial nephrectomy with patients randomized to surgery alone.
SECONDARY OBJECTIVES:
I. To evaluate for differences in recurrence-free survival associated with perioperative
nivolumab compared to surgery alone among the subset of patients with clear cell histology.
II. To compare the overall survival between the two arms. III. To describe the safety and
tolerability of perioperative nivolumab.
CORRELATIVE OBJECTIVES:
I. To correlate the primary tumor's expression of programmed cell death 1 ligand 1 (PD-L1)
with outcome.
II. To correlate the expression of PD-L1 on tumor tissue at recurrence with outcome.
III. To archive images for central confirmation of recurrence and for future correlative work
with American College of Radiology Imaging Network (ACRIN), including markers predicting
outcome or response.
IV. To prospectively collect tumor and biologic specimens (e.g., serum, peripheral blood
mononuclear cells [PBMCs]) for future correlative studies.
V. To characterize the pharmacokinetics of nivolumab and explore exposure response
relationships with respect to safety and efficacy.
VI. To characterize the immunogenicity of nivolumab.
QUALITY OF LIFE OBJECTIVES:
I. To evaluate differences in change from baseline in patient-reported symptoms and
toxicities among patients randomized to treatment with nivolumab compared to surgery alone.
OTHER EXPLORATORY OBJECTIVES:
I. To explore descriptively the efficacy of treatment with nivolumab in patients with
non-clear cell (including unclassified) histologies.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive nivolumab intravenously (IV) over 30-60 minutes on day 1. Treatment
repeats every 14 days for 2 courses. Patients then undergo partial or radical nephrectomy.
Patient then receive nivolumab over 30-60 IV on day 1. Treatment repeats every 14 days for 6
courses, and then every 28 days for 6 courses in the absence of disease progression or
unacceptable toxicity.
Patients enrolled after Amendment 4 receive nivolumab IV over 30-60 minutes on day 1..
Patients then undergo partial or radical nephrectomy. Patient then receive nivolumab IV over
30-60 minutes on day 1. Treatment repeats every 4 weeks for 9 courses in the absence of
disease progression or unacceptable toxicity.
ARM II: Patients undergo partial or radical nephrectomy followed by observation.
After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 3 years, and every 12 months for 5 years.
I. To compare recurrence-free survival (RFS) between patients with locally advanced renal
cell carcinoma randomly assigned to perioperative nivolumab in conjunction with radical or
partial nephrectomy with patients randomized to surgery alone.
SECONDARY OBJECTIVES:
I. To evaluate for differences in recurrence-free survival associated with perioperative
nivolumab compared to surgery alone among the subset of patients with clear cell histology.
II. To compare the overall survival between the two arms. III. To describe the safety and
tolerability of perioperative nivolumab.
CORRELATIVE OBJECTIVES:
I. To correlate the primary tumor's expression of programmed cell death 1 ligand 1 (PD-L1)
with outcome.
II. To correlate the expression of PD-L1 on tumor tissue at recurrence with outcome.
III. To archive images for central confirmation of recurrence and for future correlative work
with American College of Radiology Imaging Network (ACRIN), including markers predicting
outcome or response.
IV. To prospectively collect tumor and biologic specimens (e.g., serum, peripheral blood
mononuclear cells [PBMCs]) for future correlative studies.
V. To characterize the pharmacokinetics of nivolumab and explore exposure response
relationships with respect to safety and efficacy.
VI. To characterize the immunogenicity of nivolumab.
QUALITY OF LIFE OBJECTIVES:
I. To evaluate differences in change from baseline in patient-reported symptoms and
toxicities among patients randomized to treatment with nivolumab compared to surgery alone.
OTHER EXPLORATORY OBJECTIVES:
I. To explore descriptively the efficacy of treatment with nivolumab in patients with
non-clear cell (including unclassified) histologies.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive nivolumab intravenously (IV) over 30-60 minutes on day 1. Treatment
repeats every 14 days for 2 courses. Patients then undergo partial or radical nephrectomy.
Patient then receive nivolumab over 30-60 IV on day 1. Treatment repeats every 14 days for 6
courses, and then every 28 days for 6 courses in the absence of disease progression or
unacceptable toxicity.
Patients enrolled after Amendment 4 receive nivolumab IV over 30-60 minutes on day 1..
Patients then undergo partial or radical nephrectomy. Patient then receive nivolumab IV over
30-60 minutes on day 1. Treatment repeats every 4 weeks for 9 courses in the absence of
disease progression or unacceptable toxicity.
ARM II: Patients undergo partial or radical nephrectomy followed by observation.
After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months for 3 years, and every 12 months for 5 years.
Inclusion Criteria:
- ELIGIBILITY CRITERIA FOR PREREGISTRATION (STEP 0):
- Patients with a renal mass consistent with a clinical stage >= T2Nx renal cell
carcinoma (RCC) or TanyN+ RCC for which radical or partial nephrectomy is planned
- If histological confirmation of RCC has not been done within 12 months prior to
pre-registration (Step 0), patient must be willing to undergo a core biopsy for this
purpose if randomized to Arm H
- NOTE: This can be a (1) standard of care diagnostic biopsy or (2) a research
biopsy following assignment to Arm H; if the biopsy performed following
pre-registration (Step 0) clearly demonstrates a benign condition or a different
type of cancer, the patient is not eligible for registration (Step 1); a
non-diagnostic biopsy is considered a good faith effort and does not need to be
repeated unless deemed clinically necessary by the treating investigator
- NOTE: Patients randomized to Arm O are permitted to register to Step 1 (Arm B)
immediately following pre-registration assignment to Arm O, regardless of if they
have had or have not had standard of care diagnostic biopsy
- Patients must have no clinical or radiological evidence of distant metastases (M0)
unless the presumed M1 disease can be resected/definitively treated (e.g., thermal
ablation, stereotactic radiation) at the same time or within a 12 week window from the
date of the initial procedure such that the patient is considered "no evidence of
disease" (M1 NED)
- Permitted sites of oligo-metastases: lung, adrenal, nodes, pancreas, soft tissue
or skin; liver or bone metastases are not permitted
- No more than 3 metastases are permitted and all must be able to be removed or
definitively treated within 12 weeks of the primary tumor resection
- No prior systemic or local anti-cancer therapy for the current RCC is permitted;
examples of these prohibited therapies include:
- Partial nephrectomy for prior RCC
- Mastectomy for RCC
- Radiation therapy to the renal bed or any distant metastatic sites
- Current or past antineoplastic systemic therapies for RCC: i.e., chemotherapy,
hormonal therapy, immunotherapy, or standard or investigational agents for
treatment of RCC
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or
anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell
co-stimulation or checkpoint pathways
- Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1
- Women of childbearing potential and sexually active males must be strongly advised to
use accepted and effective methods of contraception, as described in the informed
consent form (ICF), or to abstain from sexual intercourse for the duration of their
participation in the study; women of childbearing potential should use adequate
methods to avoid pregnancy for 23 weeks after the last dose of nivolumab; sexually
active males should use adequate methods to avoid pregnancy for 31 weeks after the
last dose of nivolumab
- Patient must have no prior history of RCC that was resected with curative intent
within the past 5 years
- Patients with a prior RCC that was treated > 5 years before, are eligible if the
current tumor is consistent with a new primary in the opinion of the treating
investigator
- Patients with bilateral synchronous RCCs are eligible if they can be resected or
definitively treated at the same time or within a 12 week window from time of
initial nephrectomy (partial or radical) or procedure and maintain adequate
residual renal function; the patient is not eligible if both kidneys are
completely removed and subsequent hemodialysis is required
- Permitted forms of local therapy for second tumor:
- Partial or radical nephrectomy
- If tumor is =< 3cm: thermal ablation (e.g., radiofrequency ablation,
cryoablation or stereotactic radiosurgery)
- Patients must not have concurrent malignancies, with the following exceptions:
- Adequately treated basal cell or squamous cell skin cancer
- In situ cervical cancer
- A history of superficial Ta urothelial cancer is permitted (as long as not
currently undergoing treatment) whereas T1 or greater disease is excluded if
< 3 years from diagnosis; concurrent persistent disease is not permitted
- Adequately treated Stage I or II cancer from which the patient is currently
in complete remission
- Any other cancer and stage from which the patient has been disease-free for
at least 3 years prior to the time of pre-registration and as long as they
are not receiving any current treatment (e.g. adjuvant or maintenance
systemic or local therapy)
- Concurrent low risk prostate cancer on active surveillance
- No active known or suspected autoimmune disease; the following autoimmune disorders
are permitted: patients with vitiligo, type I diabetes mellitus, controlled/stable
hypothyroidism due to autoimmune or non-autoimmune conditions (hormone replacement is
allowed), psoriasis not requiring systemic treatment, or other conditions not expected
to recur
- No ongoing condition requiring systemic treatment with either corticosteroids (> 10 mg
daily prednisone equivalent) or other immunosuppressive medications with the
exceptions outlined below; no treatment with other immunosuppressive agents within 14
days prior to the first dose of study drug with the following exceptions:
- Topical, ocular, intra-articular, intranasal, inhaled steroids and adrenal
replacement steroid doses > 10 mg daily prednisone or the equivalent are
permitted in the absence of active autoimmune disease
- A brief (less than 3 weeks) course of corticosteroids (any amount) for
prophylaxis (for example: contrast dye allergy) or for treatment of
non-autoimmune conditions (for example: nausea, delayed-type hypersensitivity
reaction caused by a contact allergen) is permitted
- No uncontrolled adrenal insufficiency
- No known chronic active liver disease or evidence of acute or chronic hepatitis B
virus (HBV) or hepatitis C virus (HCV)
- No serious intercurrent illness, including ongoing or active infection requiring
parenteral antibodies
- No known evidence of human immunodeficiency virus (HIV) infection
- No known medical condition (e.g. a condition associated with uncontrolled diarrhea
such as ulcerative colitis or acute diverticulitis) that, in the investigator's
opinion, would increase the risk associated with study participation or interfere with
the interpretation of safety results
- No major surgery within 28 days prior to randomization
- No patients currently enrolled in other clinical trials testing a therapeutic
intervention
- No history of severe hypersensitivity to a monoclonal antibody
- Signed, dated informed consent
- ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1):
- Patients must meet all Step 0 eligibility criteria at the time of their registration
to Step 1
- In patients randomized to Arm H, core tumor biopsy must demonstrate RCC of any
histology, including sarcomatoid, unclassified, or "unknown histology" (if
preoperative biopsy was uninformative)
- NOTE: A non-diagnostic biopsy is considered a good faith effort and does not need
to be repeated unless deemed clinically necessary by the treating investigator
- Women must not be pregnant or breast-feeding; all females of childbearing potential
must have a blood test or urine study within 2 weeks prior to registration to rule out
pregnancy; a female of childbearing potential is any woman, regardless of sexual
orientation or whether they have undergone tubal ligation, who meets the following
criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy, or
- Has not been naturally postmenopausal for at least 24 consecutive months (i.e.,
has had menses at any time in the preceding 24 consecutive months)
- White blood cells >= 2000/uL, within 8 weeks of registration
- Absolute neutrophil count (ANC) >= 1,500/mm^3, within 8 weeks of registration
- Platelet count >= 100,000/mm^3, within 8 weeks of registration
- Hemoglobin >= 9.0 g/dL, within 8 weeks of registration
- Serum creatinine =< 1.5 x upper limit of normal (ULN) (except subjects with Gilbert
Syndrome, who can have total bilirubin < 3.0 x ULN), within 8 weeks of registration
- Total bilirubin =< 1.5 x ULN (except subjects with Gilbert syndrome, who can have
total bilirubin < 3.0 x ULN), within 4 weeks of randomization
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN,
within 8 weeks of registration
We found this trial at
281
sites
Allentown, Pennsylvania 18103
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
361 Old Belgrade Road
Augusta, Maine 04330
Augusta, Maine 04330
(207) 621-6100
Principal Investigator: Peter Rubin
Phone: 207-626-4855
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Lauren C. Harshman
Phone: 877-442-3324
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Lauren C. Harshman
Phone: 617-667-9925
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
Burlington, Vermont 05401
802-656-8990
Principal Investigator: Scott D. Perrapato
Click here to add this to my saved trials
4725 North Federal Highway
Fort Lauderdale, Florida 33308
Fort Lauderdale, Florida 33308
(954) 771-8000
Principal Investigator: Leonard J. Seigel
Phone: 954-267-7750
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
Galveston, Texas 77555
(409) 772-1011
Principal Investigator: Bagi R. Jana
Phone: 409-772-1950
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: John C. Henegan
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Timothy J. Daskivich
Phone: 310-423-8965
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
593 Eddy Street
Providence, Rhode Island 02903
Providence, Rhode Island 02903
401-444-4000
Principal Investigator: Anthony E. Mega
Phone: 401-444-1488
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: Michael A. Liss
Phone: 210-450-3800
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Charles O. Kim
Phone: 808-486-6000
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
Click here to add this to my saved trials
Anaheim, California 92806
Principal Investigator: Helen H. Moon
Phone: 800-398-3996
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Ajjai S. Alva
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
Antigo, Wisconsin 54409
Principal Investigator: Harish G. Ahuja
Phone: 715-623-9869
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Viraj Master
Phone: 404-778-1868
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Bakersfield, California 93301
Principal Investigator: Primo N. Lara
Phone: 661-323-4673
Click here to add this to my saved trials
Baldwin Park, California 91706
Principal Investigator: Helen H. Moon
Phone: 800-398-3996
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Michael A. Carducci
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
4950 Essen Lane
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-757-0343
Click here to add this to my saved trials
Baton Rouge, Louisiana 70805
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
118 Northport Avenue
Belfast, Maine 04915
Belfast, Maine 04915
Principal Investigator: Peter Rubin
Phone: 207-338-2500
Click here to add this to my saved trials
Bellflower, California 90706
Principal Investigator: Helen H. Moon
Phone: 800-398-3996
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Berlin, Vermont 05602
Principal Investigator: Scott D. Perrapato
Phone: 802-225-5400
Click here to add this to my saved trials
Biddeford, Maine 04005
Principal Investigator: Peter Rubin
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
Boone, Iowa 50036
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Lauren C. Harshman
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Boston, Massachusetts 02118
Principal Investigator: Gretchen A. Gignac
Phone: 617-638-8265
Click here to add this to my saved trials
55 Fruit St
Boston, Massachusetts 02114
Boston, Massachusetts 02114
(617) 724-4000
Principal Investigator: Lauren C. Harshman
Phone: 877-726-5130
Massachusetts General Hospital Cancer Center An integral part of one of the world
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Benjamin A. Gartrell
Phone: 718-904-2730
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Benjamin A. Gartrell
Phone: 718-379-6866
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Benjamin A. Gartrell
Phone: 718-379-6866
Click here to add this to my saved trials
Bronx, New York 10468
Principal Investigator: Yeun-Hee A. Park
Phone: 718-584-9000
Click here to add this to my saved trials
Burlington, Massachusetts 01805
Principal Investigator: Krishna S. Gunturu
Phone: 781-744-8027
Click here to add this to my saved trials
Burlington, Wisconsin 53105
Principal Investigator: Antony Ruggeri
Phone: 414-302-2304
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Canton, Michigan 48188
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
Principal Investigator: Tracy L. Rose
Phone: 877-668-0683
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Stephen J. Savage
Phone: 843-792-9321
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
775 South Main Street
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: Walter M. Stadler
Phone: 773-702-8222
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Chicago, Illinois 60611
Principal Investigator: Jeffrey A. Sosman
Phone: 312-695-1301
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
Chicago, Illinois 60612
(312) 942-5000
Principal Investigator: Timothy M. Kuzel
Phone: 312-942-5498
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
Click here to add this to my saved trials
Cincinnati, Ohio 45219
Principal Investigator: Abhinav Sidana
Phone: 513-558-4553
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Cincinnati, Ohio 45220
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Clackamas, Oregon 97015
Principal Investigator: Alison K. Conlin
Phone: 503-215-2614
Click here to add this to my saved trials
Clinton, North Carolina 28328
Principal Investigator: Nagesh H. Jayaram
Phone: 919-587-9077
Click here to add this to my saved trials
Clinton, South Carolina 29325
Principal Investigator: Jeffrey K. Giguere
Phone: 844-651-1233
Click here to add this to my saved trials
Clive, Iowa 50325
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
12495 University Ave
Clive, Iowa 50325
Clive, Iowa 50325
(515) 358-9700
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Mercy Cancer Center - West Lakes When it comes to cancer care, there
Click here to add this to my saved trials
1400 East Boulder Street
Colorado Springs, Colorado 80909
Colorado Springs, Colorado 80909
Principal Investigator: Geetika Srivastava
Phone: 719-365-2406
Click here to add this to my saved trials
1 Hospital Dr
Columbia, Missouri 65212
Columbia, Missouri 65212
(573) 882-2100
Principal Investigator: Puja Nistala
Phone: 573-882-7440
University of Missouri-Ellis Fischel Ellis Fischel Cancer Center's team of physician specialists and other trained...
Click here to add this to my saved trials
1203 South Tyler Street
Covington, Louisiana 70433
Covington, Louisiana 70433
Principal Investigator: David S. Hanson
Phone: 225-215-1353
Click here to add this to my saved trials
10 Barnes West Drive
Creve Coeur, Missouri 63141
Creve Coeur, Missouri 63141
Principal Investigator: Joel Picus
Phone: 800-600-3606
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Vitaly Margulis
Phone: 214-648-7097
Click here to add this to my saved trials
100 North Academy Avenue
Danville, Pennsylvania 17822
Danville, Pennsylvania 17822
570-271-6211
Principal Investigator: Heinric Williams
Phone: 570-271-5251
Geisinger Medical Center Since 1915, Geisinger Medical Center has been known as the region’s resource...
Click here to add this to my saved trials
Decatur, Georgia 30033
Principal Investigator: Wayne B. Harris
Phone: 404-321-6111
Click here to add this to my saved trials
210 West McKinley Avenue
Decatur, Illinois 62526
Decatur, Illinois 62526
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
Des Moines, Iowa 50314
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
1111 6th Ave
Des Moines, Iowa 50314
Des Moines, Iowa 50314
(515) 247-3121
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Mercy Medical Center - Des Moines Mercy Medical Center
Click here to add this to my saved trials
4160 John R St #2122
Detroit, Michigan 48201
Detroit, Michigan 48201
(313) 833-1785
Principal Investigator: Ulka N. Vaishampayan
Phone: 313-576-9790
Wayne State University/Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Jeffrey Crawford
Phone: 888-275-3853
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
Easley, South Carolina 29640
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
Click here to add this to my saved trials
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
155 E. Brush Hill Road
Elmhurst, Illinois 60126
Elmhurst, Illinois 60126
(331) 221-1000
Principal Investigator: Brian C. Myre
Phone: 630-758-5460
Elmhurst Memorial Hospital When it comes to medical care, you have a lot of options....
Click here to add this to my saved trials
101 S Major St
Eureka, Illinois 61530
Eureka, Illinois 61530
309-467-2371
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Eureka Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
801 Broadway North
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
Click here to add this to my saved trials
Fargo, North Dakota 58122
Principal Investigator: Preston D. Steen
Phone: 701-234-6161
Click here to add this to my saved trials
165 North University Avenue
Farmington, Utah 84025
Farmington, Utah 84025
Principal Investigator: Brock O'Neil
Phone: 888-424-2100
Click here to add this to my saved trials
Farmington Hills, Michigan 48334
Principal Investigator: Ulka N. Vaishampayan
Phone: 313-576-9363
Click here to add this to my saved trials
Fitchburg, Massachusetts 01420
Principal Investigator: Kriti Mittal
Phone: 978-343-5670
Click here to add this to my saved trials
Fond Du Lac, Wisconsin 54937
Principal Investigator: Antony Ruggeri
Phone: 414-302-2304
Click here to add this to my saved trials
Fontana, California 92335
Principal Investigator: Helen H. Moon
Phone: 800-398-3996
Click here to add this to my saved trials
1024 S Lemay Ave
Fort Collins, Colorado 80524
Fort Collins, Colorado 80524
(970) 495-7000
Principal Investigator: Geetika Srivastava
Phone: 970-297-6150
Poudre Valley Hospital A 270-bed regional medical center offering a wide array of treatments, surgeries,...
Click here to add this to my saved trials
Fort Dodge, Iowa 50501
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
Click here to add this to my saved trials
Fruitland, Idaho 83619
Principal Investigator: Alison K. Conlin
Phone: 907-212-6871
Click here to add this to my saved trials
3315 N Seminary St
Galesburg, Illinois 61401
Galesburg, Illinois 61401
309-344-9269
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Galesburg Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
Click here to add this to my saved trials
Geneva, Illinois 60134
Principal Investigator: Michael Kahn
Phone: 630-315-1918
Click here to add this to my saved trials
Germantown, Wisconsin 53022
Principal Investigator: Antony Ruggeri
Phone: 414-302-2304
Click here to add this to my saved trials
Glens Falls, New York 12801
Principal Investigator: Scott D. Perrapato
Phone: 518-926-6700
Click here to add this to my saved trials
Goldsboro, North Carolina 27534
Principal Investigator: Nagesh H. Jayaram
Phone: 919-587-9077
Click here to add this to my saved trials